Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878758 · ClinicalTrials.gov registry record · NA
Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles
A NA study, sponsored by Becton, Dickinson and Company.
- Completed
- Registry status
- NA
- Development phase
- 158
- Enrollment target
NCT03878758 is a NA study that has completed, run by Becton, Dickinson and Company. The registered enrollment target is 158 participants.
The verdict
NCT03878758, a NA study, has completed, sponsored by Becton, Dickinson and Company.
- COMPLETED
- Registry status
- NA
- Development phase
- 158 participants
- Enrollment target
Study Summary
This is a subject partially blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. three (3) thinner commercially available comparator pen needles (Artsana Insupen Extr3me 33G, Artsana Insupen Extr3me 34G and the Simple Diagnostics Comfort EZ™ 33G Pen Needles). The study will include up to 146 study subjects having Type 1 or Type 2 diabetes.
Interventions
- DEVICE BD Nano™ PRO
- DEVICE 33G Artsana Insupen Extr3me
- DEVICE 34G Artsana Insupen Extr3me
- DEVICE Simple Diagnostics Comfort EZ™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2019-02-07 |
| Est. Completion | 2019-04-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878758
The ClinicalTrials.gov registry entry for NCT03878758 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 158 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Becton, Dickinson and Company, which has 33 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which BD Nano™ PRO is the first listed.
NCT03878758 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878758 about?
NCT03878758 is a clinical study titled "Comparative User Experiences With BD Nano™ PRO 4mm x 32G Extra Thin Wall Pen Needle vs Three Commercially Available Pen Needles". This is a subject partially blinded, block randomized, prospective, single-visit, multi-center study to compare user experiences with BD Nano™ PRO pen needle vs. three (3) thinner commercially available comparator pen needles (Artsana Insupen Extr3me 33G, Artsana Insupen Extr3me 34G and the Simple D...
What is the current status of trial NCT03878758?
This trial is currently completed. It is a NA study. The enrollment target is 158 participants. The study started on 2019-02-07. Estimated completion is 2019-04-30.
What interventions are being tested in trial NCT03878758?
The interventions under investigation include: BD Nano™ PRO (DEVICE), 33G Artsana Insupen Extr3me (DEVICE), 34G Artsana Insupen Extr3me (DEVICE), Simple Diagnostics Comfort EZ™ (DEVICE).
Who is sponsoring clinical trial NCT03878758?
This trial is sponsored by Becton, Dickinson and Company, which has 33 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.